February 06, 2012

Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Share this content:
Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

Sponsors and Collaborators
Amgen

Contact
Amgen Call Center
866-572-6436

Investigator
Amgen

ClinicalTrials.gov Identifier
NCT00680992

Recommended for you

Related Resources

News
You must be a registered member of Cancer Therapy Advisor to post a comment.
Click here to login   |  Click here to register

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs